Literature DB >> 30428415

New quinoline/chalcone hybrids as anti-cancer agents: Design, synthesis, and evaluations of cytotoxicity and PI3K inhibitory activity.

Samar H Abbas1, Amer Ali Abd El-Hafeez2, Mai E Shoman1, Monica M Montano3, Heba A Hassan4.   

Abstract

A series of quinoline-chalcone hybrids was designed as potential anti-cancer agents, synthesized and evaluated. Different cytotoxic assays revealed that compounds experienced promising activity. Compounds 9i and 9j were the most potent against all the cell lines tested with IC50 = 1.91-5.29 µM against A549 and K-562 cells. Mechanistically, 9i and 9j induced G2/M cell cycle arrest and apoptosis in both A549 and K562 cells. Moreover, all PI3K isoforms were inhibited non selectively with IC50s of 52-473 nM when tested against the two mentioned compounds with 9i being most potent against PI3K-γ (IC50 = 52 nM). Docking of 9i and 9j showed a possible formation of H-bonding with essential valine residues in the active site of PI3K-γ isoform. Meanwhile, Western blotting analysis revealed that 9i and 9j inhibited the phosphorylation of PI3K, Akt, mTOR, as well as GSK-3β in both A549 and K562 cells, suggesting the correlation of blocking PI3K/Akt/mTOR pathway with the above antitumor activities. Together, our findings support the antitumor potential of quinoline-chalcone derivatives for NSCLC and CML by inhibiting the PI3K/Akt/mTOR pathway.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; Cancer; Chalcone; G(2)/M arrest; PI3K pathway; Quinoline

Mesh:

Substances:

Year:  2018        PMID: 30428415      PMCID: PMC6931042          DOI: 10.1016/j.bioorg.2018.10.064

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  47 in total

1.  Relevance of drug uptake, cellular distribution and cell membrane fluidity to the enhanced sensitivity of Down's syndrome fibroblasts to anticancer antibiotic-mitoxantrone.

Authors:  Maria Przybylska; Zofia Jóźwiak
Journal:  Biochim Biophys Acta       Date:  2003-04-01

2.  Hydrazones of 2-aryl-quinoline-4-carboxylic acid hydrazides: synthesis and preliminary evaluation as antimicrobial agents.

Authors:  Kamel A Metwally; Lobna M Abdel-Aziz; El-Sayed M Lashine; Mohamed I Husseiny; Rania H Badawy
Journal:  Bioorg Med Chem       Date:  2006-09-01       Impact factor: 3.641

3.  Synthesis, molecular docking and anti-inflammatory screening of novel quinoline incorporated pyrazole derivatives using the Pfitzinger reaction II.

Authors:  Said A H El-Feky; Zakaria K Abd El-Samii; Nermine A Osman; Jasmine Lashine; Mohamed A Kamel; Hamdy Kh Thabet
Journal:  Bioorg Chem       Date:  2014-12-31       Impact factor: 5.275

4.  Synthesis and antiproliferative evaluation of 3-phenylquinolinylchalcone derivatives against non-small cell lung cancers and breast cancers.

Authors:  Chih-Hua Tseng; Yeh-Long Chen; Chih-Yao Hsu; Tzu-Chiang Chen; Chih-Mei Cheng; Hsien-Cheng Tso; Yan-Jia Lu; Cherng-Chyi Tzeng
Journal:  Eur J Med Chem       Date:  2012-11-24       Impact factor: 6.514

5.  PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways.

Authors:  V L Grandage; R E Gale; D C Linch; A Khwaja
Journal:  Leukemia       Date:  2005-04       Impact factor: 11.528

6.  Oncogenic signaling of class I PI3K isoforms.

Authors:  A Denley; S Kang; U Karst; P K Vogt
Journal:  Oncogene       Date:  2007-11-12       Impact factor: 9.867

Review 7.  Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.

Authors:  Jaclyn LoPiccolo; Gideon M Blumenthal; Wendy B Bernstein; Phillip A Dennis
Journal:  Drug Resist Updat       Date:  2007-12-31       Impact factor: 18.500

8.  Synthesis of novel quinoline-2-one based chalcones of potential anti-tumor activity.

Authors:  Rodrigo Abonia; Daniel Insuasty; Juan Castillo; Braulio Insuasty; Jairo Quiroga; Manuel Nogueras; Justo Cobo
Journal:  Eur J Med Chem       Date:  2012-09-06       Impact factor: 6.514

9.  Cancer incidence in egypt: results of the national population-based cancer registry program.

Authors:  Amal S Ibrahim; Hussein M Khaled; Nabiel Nh Mikhail; Hoda Baraka; Hossam Kamel
Journal:  J Cancer Epidemiol       Date:  2014-09-21

10.  Glaucocalyxin A induces G2/M cell cycle arrest and apoptosis through the PI3K/Akt pathway in human bladder cancer cells.

Authors:  Wenfeng Lin; Jinlin Xie; Naijin Xu; Linglong Huang; Abai Xu; Hulin Li; Chaoming Li; Yubo Gao; Masami Watanabe; Chunxiao Liu; Peng Huang
Journal:  Int J Biol Sci       Date:  2018-03-10       Impact factor: 6.580

View more
  10 in total

1.  Investigating the Anticancer Activity of Isatin/Dihydropyrazole Hybrids.

Authors:  Rita Meleddu; Vilma Petrikaite; Simona Distinto; Antonella Arridu; Rossella Angius; Lorenzo Serusi; Laura Škarnulytė; Ugnė Endriulaitytė; Miglė Paškevičiu Tė; Filippo Cottiglia; Marco Gaspari; Domenico Taverna; Serenella Deplano; Benedetta Fois; Elias Maccioni
Journal:  ACS Med Chem Lett       Date:  2018-12-18       Impact factor: 4.345

Review 2.  Molecular targets and anticancer activity of quinoline-chalcone hybrids: literature review.

Authors:  Mamdouh F A Mohamed; Gamal El-Din A Abuo-Rahma
Journal:  RSC Adv       Date:  2020-08-21       Impact factor: 4.036

Review 3.  Tailored Quinolines Demonstrate Flexibility to Exert Antitumor Effects through Varied Mechanisms-A Medicinal Perspective.

Authors:  Sachin Sharma; Arshdeep Singh; Sahil Sharma; Ram Sharma; Jagjeet Singh; Nihar Kinarivala; Kunal Nepali; Jing P Liou
Journal:  Anticancer Agents Med Chem       Date:  2021       Impact factor: 2.527

4.  Design, synthesis, and anticancer evaluation of novel quinoline derivatives of ursolic acid with hydrazide, oxadiazole, and thiadiazole moieties as potent MEK inhibitors.

Authors:  Xiao-Yan Jin; Hao Chen; Dong-Dong Li; A-Liang Li; Wen-Yan Wang; Wen Gu
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

5.  Novel 1,3,5-Triazinyl Aminobenzenesulfonamides Incorporating Aminoalcohol, Aminochalcone and Aminostilbene Structural Motifs as Potent Anti-VRE Agents, and Carbonic Anhydrases I, II, VII, IX, and XII Inhibitors.

Authors:  Eva Havránková; Vladimír Garaj; Šárka Mascaretti; Andrea Angeli; Zuzana Soldánová; Miroslav Kemka; Jozef Motyčka; Marie Brázdová; Jozef Csöllei; Josef Jampílek; Claudiu T Supuran
Journal:  Int J Mol Sci       Date:  2021-12-26       Impact factor: 5.923

6.  Synthesis, delivery, and molecular docking of fused quinolines as inhibitor of Hepatitis A virus 3C proteinase.

Authors:  Mehrnaz Rafiei Jorshari; Manouchehr Mamaghani; Parivash Jahanshahi
Journal:  Sci Rep       Date:  2021-09-23       Impact factor: 4.379

7.  Ligand substituent effect on the cytotoxicity activity of two new copper(ii) complexes bearing 8-hydroxyquinoline derivatives: validated by MTT assay and apoptosis in MCF-7 cancer cell line (human breast cancer).

Authors:  Arif Ali; Somesh Banerjee; Saima Kamaal; Mohammad Usman; Neeladrisingha Das; Mohd Afzal; Abdullah Alarifi; Nayim Sepay; Partha Roy; Musheer Ahmad
Journal:  RSC Adv       Date:  2021-04-16       Impact factor: 3.361

8.  Identification of novel furo[2,3-d]pyrimidine based chalcones as potent anti-breast cancer agents: synthesis, in vitro and in vivo biological evaluation.

Authors:  Mai A Mansour; Mamdouh A Oraby; Zeinab A Muhammad; Deena S Lasheen; Hatem M Gaber; Khaled A M Abouzid
Journal:  RSC Adv       Date:  2022-03-15       Impact factor: 3.361

9.  Solvent-driven structural topology involving energetically significant intra- and intermolecular chelate ring contacts and anticancer activities of Cu(ii) phenanthroline complexes involving benzoates: experimental and theoretical studies.

Authors:  Manjit K Bhattacharyya; Utpal Saha; Debajit Dutta; Amal Das; Akalesh K Verma; Antonio Frontera
Journal:  RSC Adv       Date:  2019-05-24       Impact factor: 4.036

10.  Hybrids of Imatinib with Quinoline: Synthesis, Antimyeloproliferative Activity Evaluation, and Molecular Docking.

Authors:  Carine Santos; Luiz Pimentel; Henayle Canzian; Andressa Oliveira; Floriano Junior; Rafael Dantas; Lucas Hoelz; Debora Marinho; Anna Cunha; Monica Bastos; Nubia Boechat
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.